Fulgent Genetics Depreciation & Amortization Growth & History (FLGT)
Fulgent Genetics's depreciation and amortization was $24.1M for fiscal 2025.
View full Fulgent Genetics company overviewFulgent Genetics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.1M | −$805,000 | −3.23% |
| 2024 | 2024-12-31 | $24.9M | −$1.2M | −4.65% |
| 2023 | 2023-12-31 | $26.1M | −$6.5M | −19.96% |
| 2022 | 2022-12-31 | $32.7M | $21.7M | +196.82% |
| 2021 | 2021-12-31 | $11.0M | $8.0M | +271.51% |
| 2020 | 2020-12-31 | $3.0M | $855,000 | +40.58% |
| 2019 | 2019-12-31 | $2.1M | −$56,000 | −2.59% |
| 2018 | 2018-12-31 | $2.2M | $435,000 | +25.17% |
| 2017 | 2017-12-31 | $1.7M | $558,000 | +47.69% |
| 2016 | 2016-12-31 | $1.2M | $595,000 | +103.48% |
| 2015 | 2015-12-31 | $575,000 | $379,000 | +193.37% |
| 2014 | 2014-12-31 | $196,000 | — | — |
Fulgent Genetics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.7M | $1.6M | +26.79% |
| Q1 2026 | 2026-03-31 | $6.0M | $81,000 | +1.37% |
| Q4 2025 | 2025-12-31 | $6.1M | — | — |
| Q3 2025 | 2025-09-30 | $6.0M | $118,000 | +1.99% |
| Q2 2025 | 2025-06-30 | $6.1M | −$99,000 | −1.61% |
| Q1 2025 | 2025-03-31 | $5.9M | −$744,000 | −11.17% |
| Q3 2024 | 2024-09-30 | $5.9M | −$499,000 | −7.77% |
| Q2 2024 | 2024-06-30 | $6.2M | −$159,000 | −2.52% |
| Q1 2024 | 2024-03-31 | $6.7M | −$216,000 | −3.14% |
| Q3 2023 | 2023-09-30 | $6.4M | −$3.4M | −34.63% |
| Q2 2023 | 2023-06-30 | $6.3M | −$2.0M | −24.36% |
| Q1 2023 | 2023-03-31 | $6.9M | $2.2M | +46.52% |
| Q3 2022 | 2022-09-30 | $9.8M | $6.6M | +209.49% |
| Q2 2022 | 2022-06-30 | $8.3M | $5.9M | +245.12% |
| Q1 2022 | 2022-03-31 | $4.7M | $2.8M | +144.28% |
| Q3 2021 | 2021-09-30 | $3.2M | $2.5M | +339.47% |
| Q2 2021 | 2021-06-30 | $2.4M | $1.9M | +340.44% |
| Q1 2021 | 2021-03-31 | $1.9M | $1.4M | +237.79% |
| Q3 2020 | 2020-09-30 | $722,000 | $219,000 | +43.54% |
| Q2 2020 | 2020-06-30 | $549,000 | $38,000 | +7.44% |
| Q1 2020 | 2020-03-31 | $569,000 | $34,000 | +6.36% |
| Q3 2019 | 2019-09-30 | $503,000 | −$44,000 | −8.04% |
| Q2 2019 | 2019-06-30 | $511,000 | −$51,000 | −9.07% |
| Q1 2019 | 2019-03-31 | $535,000 | $19,000 | +3.68% |
| Q3 2018 | 2018-09-30 | $547,000 | $109,000 | +24.89% |
| Q2 2018 | 2018-06-30 | $562,000 | $157,000 | +38.77% |
| Q1 2018 | 2018-03-31 | $516,000 | $104,000 | +25.24% |
| Q3 2017 | 2017-09-30 | $438,000 | $134,000 | +44.08% |
| Q2 2017 | 2017-06-30 | $405,000 | $157,000 | +63.31% |
| Q1 2017 | 2017-03-31 | $412,000 | $213,000 | +107.04% |
| Q3 2016 | 2016-09-30 | $304,000 | $133,000 | +77.78% |
| Q2 2016 | 2016-06-30 | $248,000 | — | — |
| Q1 2016 | 2016-03-31 | $199,000 | — | — |
| Q3 2015 | 2015-09-30 | $171,000 | — | — |
Fulgent Genetics depreciation and amortization trends
Over the last five fiscal years, Fulgent Genetics's depreciation and amortization increased from $3.0M to $24.1M, a change of $21.2M. The latest reported quarter, Q2 2026, shows $7.7M.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fulgent Genetics source filings ↗